Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Accounts Payables: 2010-2024

Historic Accounts Payables for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $2.2 million.

  • China Pharma Holdings' Accounts Payables rose 37.20% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 37.20%. This contributed to the annual value of $2.2 million for FY2024, which is 4.37% down from last year.
  • As of FY2024, China Pharma Holdings' Accounts Payables stood at $2.2 million, which was down 4.37% from $2.3 million recorded in FY2023.
  • China Pharma Holdings' Accounts Payables' 5-year high stood at $2.7 million during FY2020, with a 5-year trough of $1.9 million in FY2021.
  • For the 3-year period, China Pharma Holdings' Accounts Payables averaged around $2.3 million, with its median value being $2.3 million (2023).
  • Per our database at Business Quant, China Pharma Holdings' Accounts Payables slumped by 31.44% in 2021 and then grew by 26.85% in 2022.
  • China Pharma Holdings' Accounts Payables (Yearly) stood at $2.7 million in 2020, then tumbled by 31.44% to $1.9 million in 2021, then rose by 26.85% to $2.4 million in 2022, then declined by 4.49% to $2.3 million in 2023, then dropped by 4.37% to $2.2 million in 2024.